Biomarker-Driven Lung Cancer | Clinical

Lack of Targeted Therapies for NRG1 Fusion-Positive Advanced Solid Tumors Comes to Attention

October 23, 2020

Driver alterations in neuregulin 1 fusions have recently come to light as a new target in patients with advanced or metastatic solid tumors. Multiple factors contribute to poor outcomes in this patients population with limited option for resolution.

CodeBreaK Update Shows Durable Antitumor Activity With Sotorasib In KRAS-Mutant NSCLC

October 06, 2020

Topline results from the phase 2 CodeBreaK 100 clinical trial were consistent with phase 1 data, withthe KRAS inhibitor sotorasib having achieved a satisfactory objective response rate when administered as treatment of patients with KRAS G12C–mutant non–small cell lung cancer, who had failed a median of 2 prior lines of anti-cancer therapies, which could include immunotherapy and/or chemotherapy.

Selpercatinib Induces Infrequent Hypersensitivity in RET Fusion-Positive NSCLC, Analysis Shows

October 06, 2020

Selpercatinib-related hypersensitivity reactions occurred infrequently in patients with RET fusion-positive non–small cell lung cancer, with more cases reported in patients previously treated with an immune checkpoint inhibitor, but reactions were deemed manageable with recommended guidance and supportive care.

Sotorasib Shows Early Activity in Advanced Non–Small Cell Lung Cancer

September 21, 2020

In patients with non–small cell lung cancer harboring a KRAS G12C mutation, an aberration without any FDA approved treatment options, a study showed that the investigation agent, sotorasib achieved encouraging antitumor activity.